Catalent Launches Advanced Technology for Glass-Free Delivery
Catalent Pharma Solutions recently announced it will launch its new ADVASEPT technology, for the advanced aseptic filling of injectable drugs, at the forthcoming INTERPHEX exhibition, March 18-20, at the Javits Center, New York City, NY. The new platform provides a glass-free, aseptically filled, primary container that reduces or eliminates many concerns associated with traditional glass vials, including the risk of injuries to treatment providers and patients, the potential for glass particulate contamination, and accidental breakage in transit and subsequent product wastage.
“This new technology eliminates the risk of glass particulate contamination, significantly reduces the risk of breakages and minimizes container weight through the use of an ultrapure plastic design,” said Catalent’s Jonathan Arnold, Vice President and General Manager of Advanced Delivery Technologies. “Catalent also brings analytical expertise in areas such as biologic substance testing, extractables and leachables, and stability, and we have scientifically shown comparability of a monoclonal antibody between traditional glass and ADVASEPT vials.”
ADVASEPT vial production leverages proven Quality by Design manufacturing techniques that have optimized the blow-fill-seal manufacturing process. Leveraging this form of advanced aseptic processing, a stopper is inserted during the blow-fill-seal process to create a next-generation, glass-free injectable solution, minimizing the risk of contamination by reducing particles, process steps, and human interaction. Significant reductions in controlled space requirements also drive out the operational and fixed costs of traditional vial filling while decreasing the risk of contamination.
Available with safe, easy-to-open pop-off or twist-off tops, the ADVASEPT stoppered vial is currently produced in 10-mL, 50-mL, and 100-mL sizes. ADVASEPT vials are manufactured at Catalent’s Woodstock, IL, facility and are highly customizable. Containers can be tailored to meet the unique needs of customers across many markets, such as biologics, pharmaceuticals, generics, and animal health. For more information, visit www.catalent.com/advasept.
Catalent Pharma Solutions is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance, and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,500 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and in fiscal 2013, generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, NJ. For more information, www.catalent.com.
Total Page Views: 1200
